Detalhe da pesquisa
1.
Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect.
Br J Dermatol
; 185(2): 253-262, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32652567
2.
Image-guided biopsy in the age of personalised medicine: strategies for success and safety.
Clin Radiol
; 76(2): 154.e1-154.e9, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32896425
3.
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.
Ann Oncol
; 30(11): 1821-1830, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31504139
4.
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
Ann Oncol
; 28(10): 2581-2587, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28961848
5.
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Ann Oncol
; 28(7): 1631-1639, 2017 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28475671
6.
Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830].
Ann Oncol
; 32(8): 1068, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34099371
7.
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Ann Oncol
; 30(11): 1848, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31406976
8.
Major therapeutic developments and current challenges in advanced melanoma.
Br J Dermatol
; 170(1): 36-44, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24443912
9.
Cutaneous effects of BRAF inhibitor therapy: a case series.
Ann Oncol
; 24(2): 530-537, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23035153
10.
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.
NPJ Precis Oncol
; 6(1): 13, 2022 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35233056
11.
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.
Br J Cancer
; 102(12): 1724-30, 2010 Jun 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-20531415
12.
Integrating BRAF/MEK inhibitors into combination therapy for melanoma.
Br J Cancer
; 100(3): 431-5, 2009 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-19156138
13.
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.
Ann Oncol
; 18(12): 2025-9, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17846021
14.
PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.
Clin Pharmacol Ther
; 100(6): 713-729, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27643536
15.
Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.
Oncogene
; 35(10): 1225-35, 2016 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26073081
16.
African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease.
Chest
; 114(3): 801-7, 1998 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-9743170
17.
Persistent corneal defect caused by Listeria monocytogenes.
Am J Ophthalmol
; 109(1): 97-8, 1990 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-2297040
18.
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.
Oncogene
; 28(1): 85-94, 2009 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-18794803
19.
Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels.
Br J Cancer
; 96(3): 445-9, 2007 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-17245336
20.
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.
Br J Cancer
; 95(5): 581-6, 2006 Sep 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-16880785